You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,200,088


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,200,088
Title:Sulfoalkyl ether cyclodextrin compositions
Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s): Antle; Vincent D. (Olathe, KS)
Assignee: Cydex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/789,598
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,200,088
Patent Claims: 1. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a UV-active impurity as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

2. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a UV-active drug-degrading agent that degrades aripiprazole as determined b UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

3. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to one or more UV-active drug-degrading agents selected from the group consisting of a glycosidic moiety, a ring-opened cyclodextrin species, a reducing sugar, and a glucose degradation product as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 m of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

4. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to one or more UV-active drug-degrading agents selected from the group consisting of 3,4-dideoxyglucosone-3-ene, 2-furaldehyde, and 5-hydroxymethyl-2-furaldehyde as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

5. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a UV-active drug-degrading agent formed by exposing a cyclodextrin starting material in an alkaline aqueous media to a substituent precursor at a temperature and for a period of time sufficient to produce the sulfoalkyl ether cyclodextrin as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

6. A sulfoalkyl ether cyclodextrin (SAE-CD) composition that can be readily mixed with an active agent, comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5 and less than 200 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a UV-active drug-degrading impurity as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length, wherein the SAE-CD composition comprises 2% or less of the drug-degrading impurity after the SAE-CD composition is maintained at a temperature of about 80.degree. C. for a period of about 120 minutes.

7. The SAE-CD composition of claim 6, wherein the SAE-CD composition comprises 0.5% or less of the drug-degrading impurity after the SAE-CD composition is maintained at a temperature of about 80.degree. C. for a period of about 120 minutes.

8. The SAE-CD composition of claim 1, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 500 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

9. The SAE-CD composition of claim 1, wherein the SAE-CD composition has an absorption of less than about 0.25 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 500 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

10. The SAE-CD composition of claim 1, wherein the SAE-CD composition has an absorption of less than about 0.2 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 500 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

11. The SAE-CD composition of claim 1, comprising less than 100 ppm of a phosphate.

12. The SAE-CD composition of claim 1, wherein the sulfoalkyl ether cyclodextrin is a compound of Formula (I): ##STR00005## wherein: p is 4, 5, or 6; R.sub.1 is independently selected at each occurrence from --OH--O--(C.sub.2-C.sub.6 alkylene)-SO.sub.3-T, wherein T is independently selected at each occurrence from pharmaceutically acceptable cations, provided that at least one R.sub.1 is --OH and at least one R.sub.1 is --OH--O--(C.sub.2-C.sub.6 alkylene)-SO.sub.3-T.

13. The SAE-CD composition of claim 12, wherein R.sub.1 is independently selected at each occurrence from --OH or --OH--O--(C.sub.2-C.sub.6 alkylene)-SO.sub.3-T, and -T is Na.sup.+ at each occurrence.

14. A formulation, comprising the SAE-CD composition of claim 1 and an active agent.

15. The formulation of claim 14, wherein the formulation has an active agent assay of about 98% or more when the formulation is maintained at a temperature of about 80.degree. C. for a period of about 120 minutes.

16. The formulation of claim 14, wherein the formulation has an active agent assay of about 99.5% or more when the formulation is maintained at a temperature of about 80.degree. C. for a period of about 120 minutes.

17. The formulation of claim 14, wherein the active agent is a pharmaceutically effective active agent and is present in the formulation in an effective amount.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.